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To evaluate the spectrum and regulation of matrix metalloproteinases (MMPs) in bacterial
meningitis (BM), concentrations of MMP-2, MMP-3, MMP-8, and MMP-9 and endogenous
inhibitors of metalloproteinases (TIMP-1 and TIMP-2) were measured in the cerebrospinal
fluid (CSF) of 27 children with BM. MMP-8 and MMP-9 were detected in 91% and 97%,
respectively, of CSF specimens from patients but were not detected in control patients. CSF
levels of MMP-9 were higher ( ) in 5 patients who developed hearing impairment orP ! .05
secondary epilepsy than in those who recovered without neurological deficits. Levels of MMP-
9 correlated with concentrations of TIMP-1 ( ) and tumor necrosis factor–a (P ! .001 P p
). Repeated lumbar punctures showed that levels of MMP-8 and MMP-9 were regulated.03
independently and did not correlate with the CSF cell count. Therefore, MMPs may derive
not only from granulocytes infiltrating the CSF space but also from parenchymal cells of the
meninges and brain. High concentrations of MMP-9 are a risk factor for the development of
postmeningitidal neurological sequelae.
Bacterial meningitis (BM) continues to be an important clin-
ical problem, since mortality and the incidence of neurological
sequelae remain high, despite effective antimicrobial therapy [1,
2]. In BM, acute breakdown of the blood-brain barrier (BBB),
intrathecal production of TNF-a, and accumulation of blood-
derived leukocytes in the CSF lead to brain edema, cerebral
vasculitis, and ultimately neuronal injury [3, 4]. An overactive
immune response of the host, rather than the bacterial pathogen
per se, is thought to be responsible for the neuronal damage,
resulting in hearing loss, secondary epilepsy, and cognitive im-
pairment [2, 3].
Matrix metalloproteinases (MMPs) are a family of zinc-
dependent endopeptidases that are subdivided according to
their substrate affinities for different components of the extra-
cellular matrix [5, 6]. Gelatinases (MMP-2 and MMP-9) have
been shown to induce BBB breakdown and to facilitate leu-
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kocyte extravasation in experimental BM [7] and other models
of neuroinflammation [8–12] of the central and peripheral ner-
vous systems. Collagenases (MMP-1, MMP-8, and MMP-13)
and stromelysins (MMP-3, MMP-10, and MMP-11) exert pro-
teolytic activity predominantly against fibrillar collagen types
that constitute the interstitial extracellular matrix [5]. Tissue
inhibitors of metalloproteinase-1 and -2 (TIMP-1 and TIMP-
2) are secreted as heterodimeric complexes with MMP-9 and
MMP-2, respectively, and thus modulate their proteolytic
activity [5, 6]; MMP-8, in turn, is secreted in free form [13].
TNF-a plays a pre-eminent role as the mediator of inflam-
mation in BM [14] and has been shown to induce the expression
of MMP-8 and MMP-9 in different types of leukocytes and
resident brain cells [15–19].
The upregulation of MMP-9 in human BM has been de-
scribed in an anecdotal report (2 patients) [20] and recently in
the report of a study of 19 patients [7]. However, the spectrum
of MMPs expressed in BM, their kinetic regulation, and their
role in the development of long-term neurological sequelae have
not been investigated.
In a retrospective study, we quantitated CSF concentrations
of MMP-2, MMP-3, MMP-8, and MMP-9 and of TIMP-1 and
TIMP-2 in children with BM. We correlated levels of MMPs
and TIMPs with parameters of intrathecal inflammation and
the occurrence of persistent neurological sequelae.
Patients and Methods
Patients CSF samples from 27 children (median age, 13
months; range, 6.5–45 months) with confirmed BM were evaluateds
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in a retrospective study. CSF samples from 8 children (median age,
116 months; range, 8.5–142 months) served as controls in cases in
which lumbar punctures were performed as routine follow-up after
remission of lymphocytic leukemia or when suspected CNS infec-
tion was not confirmed. The patients with confirmed BM who were
enrolled in this study were admitted 1–5 days after onset of clinical
symptoms. The diagnosis of BM was based on detection of the
pathogen in the CSF by gram staining, bacterial culture, or antigen
testing, and the presence of CSF pleocytosis.
All patients with BM were treated with either ceftriaxone
( ) or cefuroxime ( ) as part of an earlier study protocoln p 12 n p 15
[21]. Since corticosteroids strongly suppress the CSF expression of
MMP-9 [22] and possibly of other MMPs, only patients who did
not receive corticosteroid therapy were included. Clinical data were
gathered from case report files.
The development of neurological sequelae was assessed by fol-
low-up examinations, 8–10 weeks after discharge [21]. Hearing ca-
pacity was assessed by evaluation of auditory evoked brainstem
potentials or determination of behavioral responses to acoustic
stimuli. All patients with abnormal results were tested a second
time after 4–6 months. Diagnosis of sensorineural hearing loss was
based on the results of at least 2 consecutive hearing tests. Addi-
tional follow-up examinations, such as electroencephalography and
neurocranial CT or MRI, were performed if indicated.
CSF samples. Twenty CSF samples from patients with BM
were obtained by lumbar puncture at the time of admission (first
lumbar punctures) but before initiation of antibiotic therapy. Six-
teen CSF specimens were from lumbar punctures performed 12–
72 h after the initiation of antibiotic therapy. Seven patients’ CSF
from lumbar punctures performed at admission had been used for
clinical purposes, and only samples from second lumbar punctures
were available for this study. Seventeen CSF samples from 8 pa-
tients with BM who underwent serial lumbar punctures were avail-
able (1 patient had 3 consecutive spinal taps). Total cell count,
differential leukocyte count, and total protein concentration were
determined by standard methods. For measurement of MMPs,
TIMPs, and cytokines, CSF samples centrifuged at 1500g for 15
min were frozen at 2807C until assayed.
ELISAs for MMPs, TIMPs, and TNF-a. The ELISA for MMP-
2 and -3 was performed as described elsewhere [23]. ELISA kits for
MMP-8 [13], TIMP-1, and TIMP-2 [23] were obtained from Amer-
sham (Little Chalfont, UK), and kits for MMP-9 from R&D Systems
(Abingdon, UK). The ELISAs for MMPs detect proactive, active,
and inactivated MMPs. CSF samples were assayed at dilutions of
1:5 to 1:20. The sensitivity limit of assays was defined as 2 SDs
above the mean optical density of zero standard replicates. The cal-
culated detection limits with undiluted samples were as follows: 0.51
ng/mL for MMP-2, 0.055 ng/mL for MMP-3, 0.032 ng/mL for
MMP-8, 0.03 ng/mL for MMP-9, 1.25 ng/mL for TIMP-1, and 3.0
ng/mL for TIMP-2. TNF-a was determined by a high-sensitivity
ELISA (R&D Systems) that detects free and TNF-receptor–bound
forms of TNF; the detection limit was 1.3 pg/mL.
Statistical analysis. The first available CSF samples were those
obtained by lumbar punctures performed at admission ( ) orn p 20
(when these were unavailable) from second lumbar punctures
( ). Follow-up CSF samples were those from second lumbarn p 7
punctures ( ) performed for patients whose CSF samples ob-n p 8
tained at the time of admission had been analyzed for a specific
parameter (a sample from a third lumbar puncture is not included).
The intraindividual comparison of CSF levels of MMPs and
TIMPs at different time points was performed with the Student’s
paired t test. All other data sets were analyzed with use of non-
parametric statistical tests. Spearman rank correlations of levels of
MMPs or TIMPs with CSF cell count, TNF-a, and protein con-
centrations were calculated. The concentrations of MMPs, TIMPs,
and TNF-a in BM patients, grouped according to the type of
infectious agent, the time point of lumbar puncture, and the oc-
currence of neurological sequelae, were compared with use of the
Mann-Whitney U test and the Kruskal-Wallis test. Calculations of
the risk for neurological sequelae were performed with only values
for the first available CSF samples from each patient. wasP ! .05
considered significant. Samples less than the detection limit were
assigned to the value of the detection limit of the respective assays.
Results
Patients. Twenty-seven patients with BM caused by Hae-
mophilus influenzae ( ), Neisseria meningitidis ( ), orn p 14 n p 11
Streptococcus pneumoniae ( ) were included in this study.n p 2
CSF protein levels ranged from 0.28 to 5.74 g/L (median, 0.92
g/L); the numbers of leukocytes (and of granulocytes, in paren-
theses) ranged from 464 L to 16,200 /9 9(313) 3 10 / (15,400) 3 10
L (median, 4916 /L) (values from all 36 samples9[4241] 3 10
included).
All patients survived the disease, but 5 (19%) of 27 had per-
manent neurological sequelae: 3 patients had bilateral and 1
had unilateral hearing impairment, and 1 patient developed
focal epilepsy. Among 4 patients with neurological sequelae,
the infectious agent was H. influenzae, and in 1 patient it was
S. pneumoniae.
MMP-9, MMP-8, and TIMP-1 values are elevated in the CSF
of patients with BM. MMP-9 and MMP-8 were detected in
35 (97%) of 36 and 29 (91%) of 32, respectively, of CSF spec-
imens from patients with BM, whereas all control patients were
negative for both MMPs ( and ; figureP ! .001 P ! .001MMP-9 MMP-8
1A, and 1B).
TIMP-1 was constitutively expressed in the CSF of control
patients (median [range], 116 [78–1323] ng/mL; figure 1D).
Among patients with BM, concentrations of TIMP-1 were sig-
nificantly greater (750 [19.2–6424] ng/mL; ) than inn p 35
control patients ( ). In individual patients, levels ofP ! .03
TIMP-1 were closely related with those of MMP-9 (r, 0.623;
) but not with those of MMP-8 ( ).P p .0003 P p .89
Although median levels of MMP-9, MMP-8, and TIMP-1
were higher in first available than in follow-up CSF specimens
(figure 1 A, 1B, and 1D), this difference was not significant (not
shown). With assignment of the value of the detection limit of
the MMP-9 assay (0.15 ng/mL at 1:15 dilution), the MMP-
9–to–TIMP-1 ratio of control patients was (231.3 3 10 0.1–
). This ratio, a measure of proteolytic capacity [7],231.9 3 10
was strongly increased in first available (7.7 ;23[0.2–393] 3 10
) and follow-up (2.9 ; ) lumbar23n p 26 [2.0–19.2] 3 10 n p 8
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Figure 1. Concentrations of matrix metalloproteinase (MMP)-9 (A), MMP-8 (B), TNF-a (C), tissue inhibitors of metalloproteinase (TIMP)-
1 (D), and TIMP-2 (E) in the CSF (first available [v] and follow-up specimens [grey dots]) of patients with bacterial meningitis and of controls
(V). Detection limit for MMPs at the CSF dilutions used (MMP-9, 0.15 ng/mL; MMP-8, 0.32 ng/mL) are indicated by the long dotted horizontal
lines. Values from a third lumbar puncture for 1 patient are not depicted; those levels were 25 ng/mL for MMP-9, not detectable for MMP-8,
10.6 pg/mL for TNF-a, and 460 ng/mL for TIMP-1. F, Comparison of CSF levels of MMP-9 in patients without (.) and with (m) postmeningitidal
neurological sequelae. Levels of MMP-9 were significantly ( ) higher in patients with ( ) vs. those without ( ) neurologicalP ! .05 n p 5 n p 22
sequelae. Short horizontal bars indicate medians.
punctures ( ; the difference of the MMP-9–to–TIMP-1P ! .001
ratio from first available vs. follow-up lumbar punctures missed
statistical significance: ).P p .068
At the CSF dilutions used (1:15), small amounts of MMP-
2 and MMP-3 were detected in both BM and control CSF.
However, the values ranged consistently below the lowest value
of the standard curve of the ELISA (7.6 ng/mL for MMP-2
and 0.82 ng/mL for MMP-3), which precluded an accurate
comparison (not shown). Compatible with the stable expression
of MMP-2, levels of TIMP-2 were similar in BM patients (122
[114–143] ng/mL; ) and control patients (125 [120–140]n p 19
ng/mL; figure 1E).
Correlation of TNF-a with MMP-8 and -9, TIMP-1, and the
CSF cell count. Sufficient material was available from 30 CSF
samples from patients to test for the presence of TNF-a. TNF-
a was not detectable (detection limit, 1.3 pg/mL) in control
patients ( ) but was upregulated in 29 (97%) of 30 of CSFn p 5
specimens from patients; the 1 sample scoring negative was
from a follow-up lumbar puncture (figure 1C). However, the
concentrations of TNF-a were not different in first available
and follow-up lumbar punctures (not shown). Levels of TNF-
a were closely correlated with those of MMP-9 (r, 0.409;
) but not with those of MMP-8 or TIMP-1. BothP p .031
TNF-a (r, 0.529; ) and MMP-9 levels (r, 0.488;P p .034np17
) correlated with the total protein content in CSFP p .034np17
specimens taken at admission but not in those from subsequent
lumbar punctures. MMP-8 and TIMP-1 values did not cor-
relate with protein levels at any time point (not shown). The
CSF cell count (total cells, mononuclear cells, or neutrophils
only) and the disease duration before admission did not relate
to any of those parameters (TNF-a, MMP-9, MMP-8, or
TIMP-1) at any time point (not shown). Furthermore, levels
of MMP-8 and -9, TIMP-1, and TNF-a were not dependent
on the type of infectious agent (in the first lumbar puncture
specimen) or on antibiotic therapy (not shown).
Time course of MMP and TIMP-1 expression in patients with
repeated lumbar punctures. The heterogeneity of the study
population regarding acuity of disease at hospital admission
rendered the collective comparison of kinetic regulation of
MMPs, TIMP-1, and other parameters inconclusive. We there-
fore compared concentrations of CSF samples from individual
patients who had serial lumbar punctures. MMP-9 and MMP-
8 underwent rapid kinetic changes, but the absolute concen-
trations or relative changes did not relate to each other or to
the CSF cell count (not shown). At admission, levels of MMP-
9 were higher than those of MMP-8 in 3 patients and lower in
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3 others (1 patient had equal amounts of MMP-9 and MMP-
8 in the first lumbar puncture specimen). The relative kinetic
changes of TNF-a and MMP-9 in individual patients who un-
derwent repeated lumbar punctures were significantly corre-
lated (r, 0.943; ); this was not the case for TNF-aP p .035np6
and MMP-8 (not shown).
Correlation of CSF levels of MMPs with long-term clinical
outcome. To evaluate whether upregulation of MMPs rep-
resents a risk factor for the development of persistent neuro-
logical complications after BM, we compared levels of MMP-
9 and MMP-8 in first available CSF samples from patients with
( ) and without ( ) neurological sequelae. Figure 1n p 5 n p 22
F shows that median CSF concentrations of MMP-9 were 2.5
times higher ( ) in patients who developed long-termP ! .05
complications (120 ng/mL; range, 53–363 ng/mL) than in those
who recovered without deficits (47.5 ng/mL; range, not de-
tectable to 2461 ng/mL). In contrast, CSF levels of TIMP-1,
MMP-8, and TNF-a, as well as the cell count and total protein
content in the CSF, were not discriminative for the occurrence
of neurological deficits in patients with BM (not shown).
Discussion
This study demonstrates the upregulation of MMP-9 and
MMP-8 in CSF specimens from children with BM, whereas
noninflammatory CSF samples from control patients scored
negative for both proteases. The endogenous MMP inhibitor
TIMP-1 is constitutively expressed in control CSF. In patients
with BM, CSF concentrations of TIMP-1 increased in parallel
with those of MMP-9, with a 10- to 20-fold molar excess.
TIMP-1 forms heterodimers with MMP-9 and MMP-8; this
formation decreases their detectability in the ELISAs used (in-
formation from manufacturers and [13]). This might explain
why the levels of MMP-8 fell below the detection threshold in
3 CSF samples from patients with BM. In contrast, CSF con-
centrations of MMP-2, its inhibitor TIMP-2, and MMP-3 were
not upregulated in cases of BM.
Apart from the role of MMPs in BBB breakdown [7, 22] and
extravasation of inflammatory cells into the CNS, recent animal
studies suggested a role of MMPs in glial and neuronal cell
death [11], a feature of BM with serious clinical implications
[24]. In patients with persistent hearing impairment and sec-
ondary epilepsy, the median CSF level of MMP-9 was 12.5
times higher than in patients who recovered without long-term
neurological sequelae. Conversely, routine CSF parameters and
levels of TNF-a were, as found by others [25], not indicative
of persistent neurological deficits. Results of the present study
suggest that excessive increase of MMP-9 is a risk factor for
the development of postmeningitidal neurological sequelae.
CSF levels of MMP-9 in cases of BM were 10- to 1000-fold
higher than in cases of viral meningitis [26] and multiple sclerosis
[23]. Furthermore, BM is the first neuroinflammatory disease in
which the upregulation of a second metalloproteinase, MMP-8,
in the CSF can be demonstrated. MMPs have been shown to
mediate BBB damage in experimental BM [7] and in other animal
models of neuroinflammation [8, 9, 11, 16]. That MMP-9 plays
a role in BBB breakdown in human BM can be postulated by
the correlation with CSF protein content in the present and earlier
studies [7]. In light of the rapid kinetic changes of MMPs and
the sustained BBB disruption in fully established BM, this cor-
relation is restricted to early phases of disease.
MMP-9 and MMP-8 reach similar concentrations and may
have a synergistic effect on BBB breakdown. MMP-8 targets
primarily collagen types of interstitial extracellular matrix, and
its increase may also mediate parenchymal damage. MMP-8 has
been believed to be an exclusive product of granulocytes and was
therefore initially named neutrophil collagenase. In acute BM,
the cellular immune response is dominated by granulocytes, and
upregulation of MMP-8 in the CSF is therefore not surprising.
However, the lack of correlation between the number of CSF
granulocytes and the level of MMP-8 in the collective analysis,
as well as the comparison of kinetic changes in serial lumbar
puncture specimens from individual patients, suggests that cells
other than granulocytes could be additional sources of MMP-8.
This is supported by the upregulation of MMP-8 in a model of
autoimmune encephalitis in which granulocytes are not involved
[11] and in various cell types in vitro [18].
TNF-a is a strong inducer of MMP-9 in vitro [15, 17, 19] and
in experimental neuroinflammation [12, 16]. As in recent findings
concerning animal BM [27], the 2 molecules are simultaneously
upregulated in human disease. In rabbit models of BM, maximal
levels of TNF-a occurred before invasion of leukocytes into the
CSF was detectable [14, 28]. Accordingly, we have found that
upregulation of MMP-9 in CSF occurs as early as 15 min after
initiation of experimental BM [29]. Congruent with this, the find-
ings from repeated lumbar punctures demonstrate that MMP-9
is upregulated independently of MMP-8.
Adjunctive therapy with corticosteroids is used in some cen-
ters with the aim of limiting the deleterious effects of an in-
flammatory host response in infant BM. According to some
study findings, this therapeutic regimen correlates with reduc-
tions in mortality and long-term neurological morbidity [30].
However, corticosteroids may also exert detrimental effects,
since they were shown to increase hippocampal neuronal loss
in an animal model of BM [31]. Moreover, among patients
whose therapy was begun in an advanced phase of BM, the
incidence of deaths and neurological sequelae was higher in the
group that received adjunctive corticosteroid therapy than for
patients treated only with antibiotics [32].
Corticosteroids have been shown to suppress the expression
of TNF-a [33] and MMP-9 [22] in the CSF during acute CNS
inflammation. It is therefore conceivable that the beneficial effect
of corticosteroids on long-term neurological sequelae is the result
of their downregulatory effect on MMP expression, among other
factors.
In experimental BM, synthetic inhibitors of MMPs effectively
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reduced leukocyte transmigration of basal lamina layers [34]. In
early phases of experimental BM, they decreased CSF pleocytosis
and the development of intracranial pressure [7]. In rats with
fully established BM, systemic pretreatment with the MMP in-
hibitor GM6001 lowered the CSF concentrations of MMP-9 and
TNF-a, and, most important, diminished cortical damage [27].
Other than corticosteroids, which act predominantly on tran-
scriptional regulation, MMP inhibitors have the conceptual ad-
vantage of directly antagonizing proteolytic activity of MMPs.
Present findings suggest a critical role for MMP-9 and MMP-
8 as effectors of BBB damage and of neuronal injury in human
BM. The evidence from this study and the results obtained in
a number of models of BM provide a compelling molecular
basis for future trials in which MMP inhibitors are used as
adjunctive therapy for BM.
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